Phentermine vs Tirzepatide: Which Loses More Weight?
Medically reviewed by Medical Advisory Board Last reviewed 2026-09-04
A 1959 appetite suppressant against the strongest GLP-1/GIP drug available, on results, cost, and side effects
Tirzepatide (Zepbound, Mounjaro) produces roughly two to three times more weight loss than phentermine in trial data, 15 to 20.9 percent of body weight over 72 weeks versus about 7.4 percent over 28 weeks. Phentermine costs far less and comes as a daily pill; tirzepatide is a weekly injection that costs over $1,000 a month without insurance or a manufacturer discount. Neither drug has been tested in combination with the other in a clinical trial.
Tirzepatide produces roughly two to three times more weight loss than phentermine in trial data. In the guides we publish here, that gap is the first thing worth putting a number on, because phentermine has been prescribed for weight loss since 1959 and tirzepatide only reached the market in the past few years, so it's easy to assume "newer" automatically means "better" without checking by how much.
Phentermine, a stimulant-like appetite suppressant, is approved for short-term use only and comes as a cheap daily pill. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, is a weekly injection built for long-term use and priced well above $1,000 a month before any discount. This page compares how they work, what the trial data actually shows, and who each one tends to fit.
Partner · Opt Health
Want medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Phentermine vs Tirzepatide at a Glance
The table below lines up the two drugs on the dimensions that matter most before you talk to a prescriber about either one.
| Dimension | Phentermine | Tirzepatide |
|---|---|---|
| Drug class | Sympathomimetic amine, appetite suppressant | Dual GIP/GLP-1 receptor agonist |
| Form | Daily oral pill or capsule | Weekly self-injected pen |
| FDA approval | 1959; labeled for short-term use (a few weeks) | 2022 (diabetes, as Mounjaro); 2023 (weight management, as Zepbound) |
| Average weight loss in trials | About 7.4% of body weight over 28 weeks (15 mg dose) | 15% to 20.9% of body weight over 72 weeks (dose-dependent, SURMOUNT-1) |
| Controlled substance status | Schedule IV (federal controlled substance) | Not a controlled substance |
| Typical monthly list price | Roughly $15 to $50 as a generic | Over $1,000 without insurance or a savings program |
| Common side effects | Insomnia, dry mouth, elevated heart rate and blood pressure, jitteriness | Nausea, vomiting, diarrhea, constipation |
Weight-loss figures come from the trials described below, not from head-to-head studies pitting the two drugs against each other directly, since no such trial exists.
How Much Weight Each Drug Actually Removes
Tirzepatide's headline number comes from the SURMOUNT-1 trial, where people without diabetes lost 15% to 20.9% of their starting body weight over 72 weeks, depending on dose, against 3.1% in the placebo group. That range covers roughly 30 to 45 pounds for someone starting at 220 pounds, spread across a year and a half of treatment.
Phentermine's trial evidence covers a much shorter window, matching its short-term labeling. A 28-week randomized trial of the 15 mg dose found 7.38% average body weight loss against 2.28% on placebo, roughly 16 pounds for the same 220-pound starting point. A separate higher-dose trial (30 mg) reported 8.1 kilograms lost against 1.7 kilograms on placebo, with 95.8% of participants reaching at least 5% weight loss and 62.5% reaching at least 10%. Phentermine can produce a meaningful early drop, but the trials measuring it run for months, not the year-plus timelines tirzepatide's own trials cover, and phentermine's own label does not support taking it that long in the first place.
How Phentermine and Tirzepatide Work Differently
Phentermine works on the central nervous system, triggering the release of norepinephrine and, to a lesser extent, dopamine, which suppresses appetite and raises alertness in a way similar to older stimulant medications. That mechanism is also why it carries stimulant-type side effects and Schedule IV status: the body can build tolerance to it, and the FDA label reflects that by restricting it to short-term use.
Tirzepatide works on a completely different system. It mimics two gut hormones, GLP-1 and GIP, that slow stomach emptying, increase the feeling of fullness after a meal, and improve how the body responds to insulin. That dual mechanism is what separates tirzepatide from single-hormone GLP-1 drugs like semaglutide, and it's part of why tirzepatide's trial results run ahead of older weight-loss drugs across the board, not just against phentermine specifically. See our GLP-1 peptides guide for the fuller mechanism picture behind semaglutide, tirzepatide, and retatrutide.
Side Effects: Two Different Risk Categories
Phentermine's side effects trace directly back to its stimulant mechanism: insomnia, dry mouth, jitteriness, and increases in heart rate and blood pressure are the most commonly reported. Because of the cardiovascular effect, phentermine is generally avoided in people with uncontrolled high blood pressure, heart disease, or a history of stimulant misuse, and its Schedule IV status reflects a real, documented potential for dependence with extended use.
Tirzepatide's side effects are almost entirely gastrointestinal: nausea, vomiting, diarrhea, and constipation, most pronounced during the first few dose increases and often easing as the body adjusts. It carries its own list of rarer but more serious risks, including pancreatitis and gallbladder problems, that a stimulant like phentermine does not share. Neither side-effect profile is simply "worse"; they're different categories of risk, which is exactly the kind of detail worth raising directly with whichever prescriber writes either medication.
Cost: The Gap Is Larger Than the Weight-Loss Gap
Generic phentermine typically runs $15 to $50 a month out of pocket, since it has been off patent for decades and is widely stocked at standard pharmacies. Tirzepatide, sold under the Zepbound and Mounjaro brand names, carries a list price north of $1,000 a month. Manufacturer savings programs and insurance coverage can bring that down substantially for people who qualify, but list-to-list, the cost difference between the two drugs is far larger than the difference in how much weight either one removes. Our Mounjaro cost guide breaks down the specific savings-card and cash-pay numbers for tirzepatide in more detail.
Can You Take Phentermine and Tirzepatide Together?
No published clinical trial has tested phentermine and tirzepatide as a combination, and no major obesity-treatment guideline currently recommends stacking them. Some prescribers do combine the two off-label, reasoning that phentermine's appetite-suppressing stimulant effect and tirzepatide's hormone-based mechanism act on different pathways, but that reasoning has not been tested in a controlled study measuring whether the combination adds real extra weight loss, or how the combined cardiovascular and gastrointestinal side effects interact in practice. Anyone considering both drugs together needs that conversation with a prescriber who can weigh the specific cardiovascular risk, not a general assumption that combining two different mechanisms automatically means combining two separate benefits.
Switching From Phentermine to Tirzepatide
Because phentermine is only labeled for short-term use, a switch to tirzepatide is a common next step once someone reaches the end of a phentermine course, or plateaus on it, and wants a treatment built for the long term. There is no universal required washout period between the two, but phentermine's cardiovascular effects, particularly an elevated heart rate or blood pressure, are worth confirming have settled before starting a new medication, which is a decision a prescriber makes case by case rather than off a fixed calendar rule.
Cost Per Pound Lost: The Math Behind the Price Gap
Comparing sticker prices alone hides how differently the two drugs actually spend that money. At roughly $30 a month, phentermine's 28-week trial that produced 7.38% average weight loss, about 16 pounds for someone starting at 220 pounds, works out to roughly $105 in drug cost across that period, or about $6.50 per pound lost. Tirzepatide's list price above $1,000 a month, spent across the 72 weeks SURMOUNT-1 measured, adds up to around $16,600 for a loss of 30 to 45 pounds at the higher doses, or roughly $370 to $550 per pound before any savings card or insurance coverage. That math flips considerably for anyone whose insurance covers tirzepatide or who qualifies for a manufacturer discount, which is exactly why checking coverage before comparing sticker prices matters as much as comparing the drugs themselves.
Who This Is Not For
Phentermine is a poor fit for anyone who needs a weight-loss plan measured in years rather than weeks, since its own label does not support extended use and its stimulant effects make it inappropriate for people with uncontrolled hypertension, existing heart disease, or a history of stimulant dependence. Tirzepatide is a poor fit for anyone who cannot tolerate an injection, has a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (both contraindications on its label), or simply cannot afford or access coverage for a medication priced above $1,000 a month before assistance.
What Would Change This Answer
A real head-to-head trial directly comparing phentermine and tirzepatide, rather than separate trials measured against separate placebo groups, would sharpen this comparison considerably. A meaningful price drop for tirzepatide, whether from new manufacturer competition, a generic tirzepatide entering the market, or broader insurance coverage, would also narrow the practical gap between the two options for anyone currently priced out of the stronger drug.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
What is the main difference between phentermine and tirzepatide?
Phentermine is a stimulant-like appetite suppressant taken as a daily pill for short-term use, while tirzepatide is a weekly injected hormone-mimicking drug built for long-term weight management. Tirzepatide produces substantially more weight loss in trial data, roughly 15% to 20.9% of body weight over 72 weeks versus about 7.4% over 28 weeks for phentermine, but costs many times more per month.
Is tirzepatide stronger than phentermine for weight loss?
Yes, based on separate trial data for each drug. Tirzepatide's trials show roughly two to three times the average weight loss phentermine's trials show, though the two have never been tested against each other directly in the same study.
Can I switch from phentermine to tirzepatide?
Yes, this is a common transition once a short-term phentermine course ends or plateaus. There's no universal mandatory waiting period, but a prescriber typically confirms that phentermine's cardiovascular effects, elevated heart rate or blood pressure, have settled before starting a new medication.
Why is phentermine only approved for short-term use?
Phentermine's 1959 FDA approval predates the long-term safety trials modern weight-loss drugs require, and its stimulant mechanism carries a documented potential for tolerance and dependence with extended use, reflected in its Schedule IV controlled-substance status.
How much cheaper is phentermine than tirzepatide?
Generic phentermine typically costs $15 to $50 a month. Tirzepatide, sold as Zepbound or Mounjaro, lists above $1,000 a month before insurance or manufacturer savings programs, a gap far larger than the difference in weight-loss results between the two drugs.
What happens when you stop taking phentermine?
Because phentermine suppresses appetite through a stimulant mechanism rather than changing the body's underlying hunger signaling the way tirzepatide does, appetite commonly returns to its baseline level once the drug clears the body, and any weight lost during a short course can gradually return without a separate maintenance plan in place. This is part of why phentermine's own label restricts it to short-term use rather than positioning it as an ongoing treatment.
Can phentermine and tirzepatide be taken at the same time?
No clinical trial has tested the combination, and no major guideline recommends it. Some prescribers combine them off-label, but that decision requires individualized review of cardiovascular risk with a prescriber, not a general assumption that the combination is safe or adds extra benefit.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Want weight loss handled by a physician who works from your labs? See how Opt Health does it →
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
Tirzepatide vs Semaglutide: Which GLP-1 Wins for Weight Loss
Tirzepatide vs semaglutide: dual vs single incretin agonist compared on trials, dosing, cost.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.